Pennsylvania is currently home to 3468 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
Recruiting
This phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Leuprolide acetate is in a class of medications called gonadotropin-relea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: NRG Oncology, Philadelphia, Pennsylvania
Conditions: Adult Ovarian Granulosa Cell Tumor
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Dermatology Associates of Plymouth Meeting, Plymouth Meeting, Pennsylvania
Conditions: NonSegmental Vitiligo
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Recruiting
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Biliary Tract Cancer
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/23/2024
Locations: Clinical Research Associates Of Central PA , LLC, DuBois, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Recruiting
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/23/2024
Locations: Allegheny Health Network Cancer Institute at Mellon Pavilion, Pittsburgh, Pennsylvania
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Recruiting
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Recruiting
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Alliance Cancer Specialists, Horsham, Pennsylvania
Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Recruiting
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/23/2024
Locations: Dermdox Center For Dermatology, Sugarloaf, Pennsylvania
Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
Recruiting
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Carcinoma, Hepatocellular
A Study of EXG102-031 in Patients With wAMD (Everest)
Recruiting
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be t... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
02/23/2024
Locations: Erie Retina Research, Erie, Pennsylvania
Conditions: Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes
Recruiting
The goal of this clinical trial is to evaluate the use and effectiveness of a mobile web application (app) that is designed to educate and allow patients to manage diabetes and make sustainable lifestyle changes, and to study the impact of the app on clinical outcomes of diabetes (HA1C) and educational outcomes (Self-Efficacy for Diabetes Scale). The main question to answer is: Does the use of the Diabetes Application significantly affect clinical outcomes of diabetes and cardiometabolic risk fa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Reading Hospital, an affiliate of Tower Health, West Reading, Pennsylvania
Conditions: Diabetes Mellitus, Type 2, Diabetes Education, Lifestyle Modification
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Recruiting
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/23/2024
Locations: Temple University Hospital, Philadelphia, Pennsylvania
Conditions: Moderate to Severe Asthma